文献速递消化道肿瘤与早癌

ARID1A缺失激活mTOR信号与SOX9:胃腺癌靶向ARID1A缺陷的依据

Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting ARID1A deficiency.
PubMed 文献 · Gut · 2021-03-30

胃腺癌中染色质重塑基因ARID1A改变常见,mTOR通路在未选择患者中抑制无生存获益。研究分析ARID1A基因组改变,用小鼠胃上皮细胞及功能实验探究ARID1A缺失对mTOR信号和SOX9的影响及对mTOR抑制的敏感性。结果显示超过30%胃腺癌病例有ARID1A改变,ARID1A表达与pS6和SOX9负相关,ARID1A缺失激活pS6和SOX9并可被mTOR抑制剂靶向,提示ARID1A缺陷胃腺癌患者可考虑mTOR通路抑制策略。

要点

  • 超过30%胃腺癌病例存在ARID1A突变或缺失。
  • ARID1A表达与pS6和SOX9在胃腺癌组织及PDX中负相关。
  • ARID1A缺失增加对mTOR抑制剂敏感性,与氟尿嘧啶联用增强效果。

核心结论

  • ARID1A缺失激活胃腺癌中pS6和SOX9,可被mTOR抑制剂有效靶向,提示对ARID1A缺陷胃腺癌患者靶向mTOR通路的新治疗策略。

研究设计与样本

  • 分析胃腺癌中ARID1A基因组改变,使用CK19-Cre-Arid1Afl/fl和野生型小鼠胃上皮细胞确定Arid1A缺失导致的致癌基因激活。
  • 进行功能研究确定ARID1A缺失的意义及ARID1A缺陷癌细胞对mTOR抑制的敏感性。

主要发现

  • 超过30%胃腺癌病例有ARID1A改变(突变或缺失),ARID1A表达与pS6和SOX9在胃腺癌组织及患者来源异种移植(PDX)中负相关。
  • Arid1A-/-小鼠胃组织中mTOR信号激活(pS6增加)和SOX9核表达强烈增加,可被mTOR抑制剂RAD001削减。
  • 在胃腺癌细胞系中敲低ARID1A增加pS6和核SOX9,并增加对mTOR抑制剂的敏感性,与氟尿嘧啶联用在体外和PDX体内进一步放大。

临床怎么用

  • 对胃腺癌患者可检测ARID1A缺陷,筛选可能从mTOR抑制剂治疗中获益的亚群。
  • ARID1A缺陷胃腺癌可考虑mTOR抑制剂与氟尿嘧啶联合治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gastric adenocarcinoma (GAC) is a lethal disease with limited therapeutic options. Genetic alterations in chromatin remodelling gene AT-rich interactive domain 1A (ARID1A) and mTOR pathway activation occur frequently in GAC. Targeting the mechanistic target of rapamycin (mTOR) pathway in unselected patients has failed to show survival benefit. A deeper understanding of GAC might identify a subset that can benefit from mTOR inhibition. METHODS: Genomic alterations in ARID1A were analysed in GAC. Mouse gastric epithelial cells from CK19-Cre-Arid1Afl/fl and wild-type mice were used to determine the activation of oncogenic genes due to loss of Arid1A. Functional studies were performed to determine the significance of loss of ARID1A and the sensitivity of ARID1A-deficient cancer cells to mTOR inhibition in GAC. RESULTS: More than 30% of GAC cases had alterations (mutations or deletions) of ARID1A and ARID1A expression was negatively associated with phosphorylation of S6 and SOX9 in GAC tissues and patient-derived xenografts (PDXs). Activation of mTOR signalling (increased pS6) and SOX9 nuclear expression were strongly increased in Arid1A-/- mouse gastric tissues which could be curtailed by RAD001, an mTOR inhibitor. Knockdown of ARID1A in GAC cell lines increased pS6 and nuclear SOX9 and increased sensitivity to an mTOR inhibitor which was further amplified by its combination with fluorouracil both in vitro and in vivo in PDXs. CONCLUSIONS: The loss of ARID1A activates pS6 and SOX9 in GAC, which can be effectively targeted by an mTOR inhibitor. Therefore, our studies suggest a new therapeutic strategy of clinically targeting the mTOR pathway in patients with GAC with ARID1A deficiency.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Dong X, Song S, Li Y, et al. Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting ARID1A deficiency. Gut. 2021. PMID: 33785559. doi:10.1136/gutjnl-2020-322660

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。